secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001213900-22-071230
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed Q3 2022: loss per share $0.18; cash $160M; positive NASH and COVID-19 vaccine data
--------------------------------------------------------------------------------

- Cash and investments approximately $160M as of September 30, 2022.
- R&D expenses decreased 12% YoY to $5.3M; basic loss per share improved to $0.18 from $0.21.
- Sales & marketing expense up 169% to $463K; G&A up 60% to $3.1M due to stock-based compensation.
- Reported positive Phase 2 NASH data and positive initial Phase 1 oral COVID-19 vaccine results.
- Phase 3 oral insulin (ORMD-0801) topline data expected in January 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390022071230/0001213900-22-071230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390022071230/ea168314-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-071230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer